Monitoring concentration and lipid signature of plasma extracellular vesicles from HR+ metastatic breast cancer patients under CDK4/6 inhibitors treatment
2024

Monitoring Plasma Extracellular Vesicles in Breast Cancer Patients Under Treatment

Sample size: 44 publication 10 minutes Evidence: moderate

Author Information

Author(s): Mathilde Richard, Rosalie Moreau, Mikaël Croyal, Laurent Mathiot, Jean‐Sébastien Frénel, Mario Campone, Aurélien Dupont, Julie Gavard, Gwennan André‐Grégoire, Laëtitia Guével

Primary Institution: Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes‐Angers (CRCI2NA), Inserm CNRS, Nantes Université, France

Hypothesis

Can extracellular vesicles (EVs) serve as biomarkers to predict treatment response in HR+ metastatic breast cancer patients undergoing CDK4/6 inhibitors?

Conclusion

The study found that specific lipid profiles in plasma EVs can help predict treatment responses in breast cancer patients treated with CDK4/6 inhibitors.

Supporting Evidence

  • EV concentration was monitored in 44 HR+ metastatic breast cancer patients over a treatment period.
  • Patients were classified into resistant, intermediate, and sensitive groups based on their treatment response.
  • Distinct sphingolipid profiles were identified in EVs from resistant patients compared to sensitive ones.
  • An increase in vesiclemia was associated with accelerated disease progression.

Takeaway

Doctors can look at tiny particles in the blood called extracellular vesicles to see how well breast cancer treatments are working.

Methodology

The study involved isolating EVs from plasma, measuring their concentration, and analyzing their lipid composition to correlate with treatment responses.

Potential Biases

Potential bias in patient selection and treatment history may affect the results.

Limitations

The study's findings may not be applicable to all breast cancer subtypes or treatments beyond CDK4/6 inhibitors.

Participant Demographics

Participants included 44 HR+ metastatic breast cancer patients, average age 60, and 45 healthy women, average age 54.

Statistical Information

P-Value

0.0381

Confidence Interval

not specified

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1002/jex2.70013

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication